Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Check market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 8,003,673

« Back to Dashboard
Patent 8,003,673 protects CUBICIN and is included in one NDA. There has been one Paragraph IV challenge on Cubicin. There is one tentative approval for the compound protected by this patent. Additional details are available via the generic ingredient links below.

This patent has three patent family members in three countries.

Summary for Patent: 8,003,673

Title:Daptomycin for the treatment of biofilm and catheter salvage
Abstract: Daptomycin can be used for biofilm treatment (particularly central venous catheter salvage for S. epidermidis infected catheters). Catheter salvage with daptomycin shows rapid cidality, activity against stationary phase bacteria, and penetration and activity in biofilms. The present inventions provide formulations, methods, and articles of manufacture useful for biofilm treatment or catheter salvage involving daptomycin. Particular formulations include daptomycin in lactated Ringer's solution having a rapid kill curve against the bacteria of the biofilm.
Inventor(s): Alder; Jeffrey (Harvard, MA), Silverman; Jared (Brookline, MA), Mortin; Lawrence (Framingham, MA), Van Praagh; Andrew (Chelmsford, MA)
Assignee: Cubist Pharmaceuticals, Inc. (Lexington, MA)
Application Number:11/916,089
Patent Claim Types:
see list of patent claims
Use; Formulation; Device;
Patent Metrics:
Source: PatentQuant.com
Field: Basic materials chemistry
Back Citations: 1st percentile
Forward Citations: 7th percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Cubist Pharms Llc
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 8,003,673

PCT Information
PCT FiledMay 31, 2006PCT Application Number:PCT/US2006/021006
PCT Publication Date:December 07, 2006PCT Publication Number: WO2006/130629

International Patent Family for Patent: 8,003,673

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada2610716► subscribe
World Intellectual Property Organization (WIPO)2006130629► subscribe
Japan2008546429► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.